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Background: Repetitive transcranial magnetic stimulation (rTMS) has been found to be effective in reducing frequency
and duration of auditory verbal hallucinations (AVH). Priming stimulation, which involves high-frequency rTMS
stimulation followed by low-frequency rTMS, has been shown to markedly enhance the neural response to the
low-frequency stimulation train. However, this technique has not been investigated in recent onset schizophrenia
patients. The aim of this randomized controlled study was to investigate whether the effects of rTMS on AVH can
be enhanced with priming rTMS in recent onset schizophrenia patients.
Methods: Forty recent onset schizophrenia patients completed the study. Patients were randomized over two
groups: one receiving low-frequency rTMS preceded by priming and another receiving low-frequency rTMS
without priming. Both treatments were directed at the left temporo-parietal region. The severity of AVH and other
psychotic symptoms were assessed with the auditory hallucination subscale (AHRS) of the Psychotic Symptom Rating
Scales (PSYRATS), the Positive and Negative Syndrome Scale (PANSS) and the Clinical Global Impression (CGI).
Results: We found that all the scores of these ratings significantly reduced over time (i.e. baseline through 1, 2, 4 and
6 weeks) in both the treatment groups. We found no difference between the two groups on all measures, except for
significantly greater improvement on loudness of AVH in the group with priming stimulation during the follow-ups
(F = 2.72; p < .05).
Conclusions: We conclude that low-frequency rTMS alone and high-frequency priming of low-frequency rTMS do not
elicit significant differences in treatment of overall psychopathology, particularly AVH when given in recent onset
schizophrenia patients. Add on priming however, seems to be particularly better in faster reduction in loudness of AVH.
Keywords: Schizophrenia, Priming TMS, Transcranial magnetic stimulation, Auditory verbal hallucinations, Randomized
controlled trial, Recent onsetIntroduction
Auditory verbal hallucinations (AVH) are among the
commonly presenting positive symptoms in patients of
schizophrenia. While more than 60% of patients with
schizophrenia present with AVH [1], majority of them
respond usually to antipsychotic regimens. However,
about 25% to 30% of patients who experience AVH have* Correspondence: cricsai@gmail.com
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unless otherwise stated.been found to be unresponsive to antipsychotic medica-
tion [2]. Among the non pharmacological strategies, psy-
chological therapies have been found to be effective in
reducing their burden but not able to cause much dent
in frequency or duration [3].
Brain stimulation techniques, especially repetitive trans-
cranial magnetic stimulation (rTMS) have been found to
be effective in reducing frequency and duration of AVH.
While both low and high-frequency (including theta
burst), left and right temporo-parietal sites have been
used as paradigms, low-frequency stimulation of leftis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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comparatively effective [4].
Less commonly used novel paradigms include priming
rTMS, where low-frequency rTMS is preceded by a brief
period of high-frequency rTMS. Priming stimulation,
which involves high-frequency (6 Hz) rTMS stimulation
followed by low-frequency rTMS (1Hz), has been shown
to markedly enhance the neural response to the low-
frequency stimulation train [5] and to have greater anti-
depressant effects than low-frequency rTMS alone when
applied to right dorsolateral prefrontal cortex (DLPFC)
[6,7]. As schizophrenia is associated with cortical hyper-
excitability and deficits in cortical inhibition, it has been
suggested that enhanced inhibition with priming stimu-
lation would be more effective for refractory AVH and
better tolerated than higher frequency stimulation para-
digms [8,9]. Moreover, modulation of neural activity in the
brain areas involved in the monitoring of inner speech has
been proposed as a probable explanation for the effect of
rTMS, particularly high frequency, on AVH [10].
Two randomized sham controlled studies, so far, have
investigated this technique and found that it was not
significantly better than 1-Hz rTMS [9,11]. Both these
studies investigated patients with medication-resistant
auditory hallucinations. Understanding the need for
exploring the effects of rTMS in patients during the
initial phases of psychosis, we conducting this priming
rTMS experiment on recent onset patients with schizo-
phrenia experiencing AVH with the hypothesis that prim-
ing stimulation would enhance the inhibitory action of




Patients met diagnostic criteria for schizophrenia (using the
Diagnostic Criteria for Research (DCR) of International
Classification of Diseases - tenth edition (ICD-10)) [12].
Duration of illness for inclusion was less than 2 years. An
additional inclusion criterion was that the patients should
not have been tried on more than one antipsychotic medi-
cation on an adequate dose, for an adequate duration. Ex-
clusion criteria included a prior history of a seizure not
induced by drug withdrawal, patients receiving ECT in the
last 6 months, significant neurological illness or head
trauma, significant unstable medical condition, presence of
metallic implants, cardiac pacemakers etc., left-handedness,
current drug abuse, or inability to provide informed con-
sent. Age range was 18 to 60. Number of patients targeted
for this study was 40. A total of 63 patients were screened.
Six subjects did not agree to participate and 12 subjects did
not meet inclusion/exclusion criteria: two patients had
received ECT previously within the preceding 6 months,
three had comorbid cannabis dependence syndrome, onehad frequent exacerbations of asthma, two had frequent
episodes of headache, one had hearing impairment, and
three were hostile. A total of 45 patients were enrolled,
out of which five patients who dropped out due to differ-
ent reasons (one patient attempted suicide and sustained
serious injuries, one was diagnosed with pulmonary tuber-
culosis and three were discharged before completion of
study) (see Figure 1 for the flow diagram of the progress
through the phases of a parallel randomized trial of two
groups). All patients were inpatients and underwent regu-
lar physical examination, routine laboratory studies, and
ECG. Patients were required to remain on their psycho-
tropic medication at steady dosages for the duration of the
trial.
The study protocol was approved by the institute ethics
committee and a signed informed consent was obtained
from every patient.
TMS protocol
Patients (n = 40) were randomly allocated (using block
randomization method) to active priming rTMS - ‘ex-
perimental group’ and sham priming rTMS - ‘control
group.’ The decision to enroll a patient was always made
prior to randomization. The two groups were compar-
able in terms of age, gender, occupation, education,
marital status, drug status, past and family history, and
indices of illness severity (Table 1). Patients were studied
using a double-masked, parallel design, i.e., study partici-
pants and clinical raters remained masked to allocated
condition and parameters.
TMS stimulation parameters
A Magstim Rapid® device (MAGSTIM Ltd., Whitland,
Wales) and a figure-eight coil were utilized in the delivery
of rTMS. Stimulation was administered at 100% resting
motor threshold (RMT), which was ascertained prior to
each stimulation session. Motor threshold was based on
Rossini-Rothwell algorithm [13] defined as the lowest in-
tensity, which produced five MEP responses of at least
50 μV in ten trials. Priming stimulation was provided over
left temporo-parietal region (located according to the
International 10-20 System of Electrode Placement’s PT3
location) 6 Hz, 20 trains of 5-s duration. For the control
group same stimulation condition was used but with sham
coil. Following priming or sham priming stimulation, both
the groups received 1-Hz stimulation over the same site at
1 Hz continuous, 20-min train delivering 1,200 stimula-
tions. Both groups received a total of 10 rTMS sessions
(five days per week for 2 weeks).
Clinical measures
Clinical measures used in this study were auditory hallu-
cination subscale (AHRS) of the Psychotic Symptom
Rating Scales (PSYRATS) [14]; composite positive and
Figure 1 Flow of subjects through the study.
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Negative Syndrome Scale (PANSS) [15], and the Clinical
Global Impression (CGI) [16] scores. Assessment with
PSYRATS, PANSS, and CGI at baseline and after 1, 2, 4,
and 6 weeks was done by an independent rater to ascer-
tain double-blinding.
The primary outcome measure was AHRS scores at
completion of ten sessions of rTMS, i.e., after 2 weeks.
Scores at the end of 1 (suggesting early response), 4, and
6 weeks (suggesting maintenance of response) were sec-
ondary outcome measures. Scores on other measures
too were secondary outcome measures.
Statistical analysis
Study data were analyzed using SPSS (version 22). Statis-
tical testing was two-sided with 5% as criterion for signifi-
cance. Bonferroni correction for multiple comparisons
was applied wherever applicable. The assumption of
normality was verified by normal probability plots and
Kolmogorov-Smirnov test. The main analysis was the ef-
fect of treatment over time and group interaction between
the active and sham groups in the double-blind phase.
Group differences for sample characteristics as well as
clinical parameters were examined with independent t-testand chi-square test (wherever applicable). Overall effect of
treatment over time for the two groups was compared
employing a set of multivariate repeated measures analysis
of variance with treatment as the between-group factor
and time as the within-subject factor. Post hoc tests were
performed to look for differences across individual time
points.
Results
On comparing the socio-demographic profile, no stat-
istical significant difference could be found between
active and control groups. The medication dosage
and stimulation parameters were also comparable be-
tween the two groups (Table 1). Duration of illness
was 4.85 ± 4.38 months (range: 1–19 months) in active
priming group and 5.45 ± 4.54 (range: 1–22 months) in
sham priming group (p = 0.673). None of the patients in
active or sham group were drug naïve or drug free. The
mean duration of treatment in active and sham group
were 5.2 ± 5.17 (range: 1–18 weeks) and 4.7 ± 5.08 weeks
(range: 1–19 weeks), respectively (p = 0.769). Table 2
shows comparison of mean scores and main effects of
time, group, and time*group interaction within and
between the two groups on PANSS, AHRS, and CGI
Table 1 Comparison of socio-demographic and clinical characteristics
Variable Active group (N = 20)
(mean ± SD)/N (%)
Sham group (N = 20)
(mean ± SD)/N (%)
t/χ2 df p
Age in years 31.35 ± 7.13 29.30 ± 8.71 0.815 38 0.420
Education Illiterate 4(20) 0(0) 4.224 2 0.167
≤10th class 7(35) 8(40)
>10th class 9(45) 12(60)
Occupation Unemployed 5(25) 8(40) 1.026 1 0.311
Working 15(75) 12(60)
Marital status Single 8(40) 10(50) 0.404 1 0.525
Married 12(60) 10(50)
Habitat Rural 13(65) 18(90) 3.584 1 0.127
Urban 7(35) 2(10)
Family type Nuclear 2(10) 4(20) 0.784 1 0.661
Joint/extended 18(90) 16(80)
Income (per month) <3,000 8(40) 7(35) 0.477 2 0.788
3,000–6,000 5(25) 7(35)
>6,000 7(35) 6(30)
Diagnosis F20.0 18(90) 14(70) 2.50 1 0.235
Others 2(10) 6(30)
Treatment (chlorpromazine equivalent/day) 499.77 ± 231.52 404.06 ± 181.39 1.455 38 0.154
Motor threshold Priming 37.20 ± 7.78 38.25 ± 8.01 −0.421 38 0.676
Stimulation (1-Hz stimulation) 41.50 ± 8.60 42.50 ± 10.21 −0.361 38 0.720
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significantly reduced over time (i.e., baseline through
6 weeks). These significant reductions persisted even
after applying Bonferroni correction for multiple com-
parisons (i.e., p < .0125 for PANSS, p < .0042 for AHRS,
and p < .0167 for CGI scores, respectively). However,
except for the loudness subscale of AHRS, no other
score showed significance between groups or time*group
interaction. Loudness showed significant time*group
interaction (F = 2.72; p < .05). Specifically, there was sig-
nificant difference in the reduction in scores at first week
compared to baseline. Active priming showed significant
reduction in loudness at first week compared to baseline
(p < .001), and sham priming did not result in significant
change (Figure 2). Here, we also see that reduction
through first week to sixth week in the two groups is sta-
tistically not significantly different.
Discussion
To the knowledge of the authors, this is the first random-
ized sham-controlled trial comparing high-frequency
priming of low-frequency rTMS for early phase treat-
ment of AVH in recent onset schizophrenia subjects.
In accordance with the existing evidence on the effect
of low-frequency stimulation of left temporo-parietal
site for treating AVH [4], our study groups (both)showed a significant reduction in the AVH scores (on
all studied vectors). Interestingly, significant reduction
over treatment sessions was found on overall positive,
negative, and general psychopathology as well as clin-
ical global improvement. Effect sizes, for our results
varied from 0.47 (on control vector of AHRS) to 0.90
(PANSS total score), were comparatively larger than
the earlier studies.
The two other trials [9,11] using priming rTMS for
AVH found this paradigm did not lead to significant
improvement over sham treatment; they found low-
frequency stimulation alone also to be ineffective in treat-
ing AVH. Our study found active and sham priming of
low-frequency rTMS did not show significant differences
in reducing AVH. These earlier studies used 20 min of the
total stimulation while we used 25 min of total stimula-
tion; it took lesser number of total sessions (ten compared
to 15 in earlier studies) for the current finding. Another
important methodological difference was the intensity of
stimulation. While Blumberger et al. [9] used 90% of RMT
for priming and 115% for 1-Hz stimulation and Slotema
et al. [11] used 80% of RMT for priming and 90% for 1-Hz
stimulation, we used 100% RMT intensity for both stimu-
lation frequencies.
In our study, it was observed that while both primed
and sham primed low-frequency rTMS resulted in













Frequency Baseline 3.50 ± 0.89 2.80 ± 0.90 Time 112.71 <0.001 0.75 1.00
1 week 2.35 ± 0.81 1.95 ± 1.10 Group 1.03 0.32 0.03 0.17
2 weeks 1.05 ± 1.10 1.00 ± 1.10 Group*time 2.04 0.09 0.05 0.60
4 weeks 0.75 ± 0.97 0.70 ± 0.86
6 weeks 0.80 ± 1.20 0.70 ± 0.92
Duration Baseline 2.75 ± 0.85 2.35 ± 0.75 Time 116.02 <0.001 0.75 1.00
1 week 1.80 ± 0.83 1.45 ± 0.69 Group 1.22 0.28 0.03 0.19
2 weeks 0.80 ± 0.77 0.70 ± 0.66 Group*time 0.89 0.44 0.02 0.28
4 weeks 0.65 ± 0.88 0.60 ± 0.75
6 weeks 0.60 ± 0.99 0.40 ± 0.50
Location Baseline 4.00 ± 0.00 3.85 ± 0.73 Time 40.08 <0.001 0.51 1.00
1 week 3.70 ± 0.73 3.45 ± 0.94 Group 0.41 0.50 0.01 0.10
2 weeks 2.30 ± 1.95 2.20 ± 1.88 Group*time 0.10 0.93 0.003 0.07
4 weeks 1.80 ± 2.04 1.45 ± 1.70
6 weeks 1.60 ± 2.01 1.25 ± 1.65
Loudness Baseline 2.60 ± 0.68 2.15 ± 0.75 Time 111.28 <0.001 0.75 1.00
1 week 1.70 ± 0.66 1.35 ± 0.67 Group 0.55 0.46 0.01 0.14
2 weeks 0.75 ± 0.72 0.85 ± 0.88 Group*time 2.72 0.03 0.07 0.74
4 weeks 0.55 ± 0.69 0.60 ± 0.75
6 weeks 0.45 ± 0.60 0.45 ± 0.60
Origin of voices Baseline 4.00 ± 0.00 4.00 ± 0.00 Time 40.59 <0.001 0.60 1.00
1 week 4.00 ± 0.00 3.75 ± 0.91 Group 0.01 0.91 0.00 0.05
2 weeks 2.30 ± 1.95 2.20 ± 1.94 Group*time 0.15 0.88 0.004 0.07
4 weeks 1.65 ± 1.93 1.80 ± 2.04
6 weeks 1.45 ± 1.88 1.45 ± 1.88
Amount of negative content Baseline 2.75 ± 0.77 2.50 ± 0.76 Time 58.77 <0.001 0.61 1.00
1 week 2.25 ± 0.85 2.10 ± 0.91 Group 0.45 0.51 0.01 0.10
2 weeks 1.30 ± 1.26 1.05 ± 1.15 Group*time 0.15 0.92 0.004 0.08
4 weeks 0.95 ± 1.23 0.90 ± 1.21
6 weeks 0.80 ± 1.20 0.60 ± 0.99
Degree of negative content Baseline 2.65 ± 1.14 2.30 ± 1.03 Time 36.28 <0.001 0.49 1.00
1 week 2.15 ± 1.04 1.65 ± 1.04 Group 0.80 0.38 0.02 0.14
2 weeks 1.15 ± 1.31 1.10 ± 1.25 Group*time 0.47 0.68 0.01 0.14
4 weeks 1.05 ± 1.47 0.80 ± 1.11
6 weeks 0.80 ± 1.32 0.60 ± 0.99
Amount of distress Baseline 2.95 ± 0.83 2.55 ± 0.76 Time 78.57 <0.001 0.67 1.00
1 week 2.15 ± 0.99 1.75 ± 0.97 Group 0.73 0.40 0.02 0.13
2 weeks 1.10 ± 1.25 1.00 ± 0.97 Group*time 0.72 0.55 0.02 0.20
4 weeks 0.80 ± 1.11 0.70 ± 0.92
6 weeks 0.60 ± 0.99 0.55 ± 0.83
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Table 2 Main effects of time, group, and time*group interaction within and between the two groups on various
outcome scales (Continued)
Intensity of distress Baseline 2.45 ± 0.95 2.20 ± 0.89 Time 78.35 <0.001 0.67 1.00
1 week 1.75 ± 0.72 1.40 ± 0.82 Group 0.80 0.38 0.02 0.14
2 weeks 0.85 ± 0.88 0.75 ± 0.71 Group*time 0.47 0.66 0.01 0.13
4 weeks 0.70 ± 0.92 0.55 ± 0.69
6 weeks 0.50 ± 0.83 0.45 ± 0.60
Disruption Baseline 3.40 ± 0.88 0.88 ± 0.56 Time 120.81 <0.001 0.76 1.00
1 week 2.55 ± 0.94 2.05 ± 0.76 Group 0.64 0.43 0.02 0.12
2 weeks 1.20 ± 1.20 1.20 ± 1.15 Group*time 1.42 0.24 0.04 0.37
4 weeks 0.90 ± 1.12 0.80 ± 1.05
6 weeks 0.65 ± 0.93 0.65 ± 0.93
Control Baseline 3.95 ± 0.22 4.00 ± 0.00 Time 33.72 <0.001 0.47 1.00
1 week 3.95 ± 0.22 3.75 ± 0.91 Group 0.01 0.91 0.00 0.05
2 weeks 2.40 ± 2.01 2.40 ± 2.01 Group*time 0.06 0.95 0.002 0.06
4 weeks 1.80 ± 2.04 1.75 ± 2.00
6 weeks 1.60 ± 2.01 1.60 ± 2.01
Total Baseline 35.00 ± 5.34 31.70 ± 5.31 Time 103.85 <0.001 0.73 1.00
1 week 28.35 ± 5.28 24.65 ± 7.81 Group 0.54 0.47 0.01 0.11
2 weeks 15.20 ± 13.22 14.45 ± 12.73 Group*time 0.48 0.67 0.01 0.13
4 weeks 11.60 ± 13.53 10.65 ± 12.30
6 weeks 8.25 ± 9.70 7.45 ± 9.69
CGI
Severity Baseline 5.25 ± 0.97 5.15 ± 0.93 Time 236.40 <0.001 0.86 1.00
1 week 4.00 ± 0.86 4.00 ± 0.86 Group 0.49 0.49 0.01 0.11
2 weeks 2.75 ± 0.79 2.95 ± 0.69 Group*time 1.71 0.16 0.04 0.45
4 weeks 2.25 ± 1.02 2.60 ± 0.99
6 weeks 1.90 ± 1.02 2.30 ± 0.80
Improvement Baseline 0.00 ± 0.00 0.00 ± 0.00 Time 202.87 <0.001 0.84 1.00
1 week 2.60 ± 0.68 2.80 ± 0.52 Group 0.69 0.41 0.02 0.13
2 weeks 1.90 ± 0.79 1.85 ± 0.59 Group*time 0.96 0.43 0.03 0.30
4 weeks 1.65 ± 0.75 1.85 ± 0.67
6 weeks 1.35 ± 0.75 1.60 ± 0.60
Efficacy Baseline 0.00 ± 0.00 0.00 ± 0.00 Time 127.29 <0.001 0.77 1.00
1 week 7.60 ± 1.96 8.15 ± 1.90 Group 0.63 0.43 0.02 0.12
2 weeks 5.25 ± 2.53 5.20 ± 2.07 Group*time 0.62 0.62 0.02 0.18
4 weeks 3.30 ± 2.43 4.20 ± 3.46
6 weeks 2.30 ± 2.25 2.90 ± 2.45
PANSS
PANSS-PS Baseline 26.65 ± 5.72 28.20 ± 13.52 Time 157.25 <0.001 0.81 1.00
1 week 19.25 ± 4.40 20.70 ± 7.81 Group 1.36 0.26 0.03 0.29
2 weeks 13.85 ± 4.52 16.45 ± 6.91 Group*time 1.23 0.27 0.03 0.19
4 weeks 11.45 ± 4.06 15.70 ± 12.43
6 weeks 10.55 ± 4.19 13.60 ± 8.11
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Table 2 Main effects of time, group, and time*group interaction within and between the two groups on various
outcome scales (Continued)
PANSS-NS Baseline 23.15 ± 4.64 23.45 ± 5.03 Time 200.78 <0.001 0.84 1.00
1 week 17.15 ± 4.59 18.60 ± 5.99 Group 0.79 0.47 0.02 0.20
2 weeks 13.70 ± 4.88 15.55 ± 4.54 Group*time 0.74 0.40 0.02 0.13
4 weeks 12.20 ± 4.23 13.40 ± 4.31
6 weeks 11.50 ± 3.52 12.45 ± 4.02
PANSS-GP Baseline 41.75 ± 7.92 39.25 ± 4.79 Time 232.36 <0.001 0.86 1.00
1 week 31.95 ± 5.61 31.00 ± 3.73 Group 2.41 0.09 0.03 0.48
2 weeks 25.70 ± 4.96 25.85 ± 2.96 Group*time 0.04 0.84 0.001 0.05
4 weeks 22.95 ± 4.91 24.45 ± 4.58
6 weeks 21.75 ± 4.70 22.25 ± 4.19
PANSS-total Baseline 91.55 ± 14.71 87.75 ± 9.83 Time 327.66 <0.001 0.90 1.00
1 week 68.70 ± 10.98 68.90 ± 9.98 Group 1.86 0.16 0.05 0.35
2 weeks 53.25 ± 12.49 54.65 ± 9.07 Group*time 0.05 0.83 0.001 0.06
4 weeks 46.60 ± 11.65 50.00 ± 11.79
6 weeks 43.95 ± 11.19 46.15 ± 11.54
Values in italics indicate statistical significance.
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duction of loudness of the hallucinatory voices. High-
frequency (6 Hz) stimulation delivered as priming might
have lead to the additional benefit in the active group.
However, studies comparing high- and low-frequency
stimulations of temporo-parietal regions have found no
significant differences (for review, see Slotema et al. [4]).
For generalizing the specific benefits of theta range fre-
quency, as used in this study, for high-frequency priming
needs further evidence. Perhaps this benefit could be opti-
mized in manipulating priming parameters further, e.g.,
the intensity and frequency of the priming stimulation.
Patients with AVH might be facilitated with increasedFigure 2 Comparison of mean difference of change in loudness scoreintensity (>100% RMT) or theta burst paradigms for prim-
ing stimulation in future studies. The study finding of
reduction in AVH in schizophrenia with low-frequency
magnetic stimulation is comparable to inhibitory stimula-
tion delivered to the left temporo-parietal area with trans-
cranial direct current stimulation (tDCS) [17]. However,
more evidence for efficacy is available for rTMS than for
tDCS, although there is a certain lack of head-to-head tri-
als comparing tDCS and rTMS [18].
While loudness vector is a clearly defined sensory
characteristic of AVH, it has been understood as one of
the most salient perceptual characteristics from a per-
spective of phenomenology. It has been suggested tos.
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and normal verbal thought [19]. Interestingly, loudness
of AVH showed significant group difference, with early
reduction in active priming group, earlier trials found
no difference between the two forms of stimulation on
any of the efficacy measures. Vercammen et al. [20]
found that activation in temporo-parietal structures
had a negative correlation with perceived loudness of
AVH. While suggesting that louder AVH take up more
resources involved in the processing of inner speech
resulting in a reduction of task-related activity, they
concluded that strong activation of the inner speech
processing network may contribute to the subjective
loudness of AVH. Our study findings imply that additional
high-frequency priming of low-frequency stimulation of
the left temporo-parietal site induce faster deactivation of
inner speech network.
Limitations
One major limitation of the study is the lack of sham
stimulation control for low-frequency rTMS, which
checked us from drawing conclusions on the efficacy
of the stimulation paradigm. Moreover, limited sample
size is a confound in generalizing the results.
Conclusion
We conclude that both low-frequency rTMS alone and
high-frequency priming of low-frequency rTMS are effect-
ive in treating overall psychopathology, particularly AVH
when given in recent onset schizophrenia patients. Add
on priming, however, seems to be particularly effective in
faster reduction in loudness of AVH.
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